Prognosis of Parkinson's disease: Time to stage III, IV, V, and to motor fluctuations

@article{Sato2006PrognosisOP,
  title={Prognosis of Parkinson's disease: Time to stage III, IV, V, and to motor fluctuations},
  author={Kenichi Sato and Taku Hatano and Kazuo Yamashiro and Maki Kagohashi and Kenya Nishioka and Nana Izawa and Hideki Mochizuki and Nobutaka Hattori and Hideo Mori and Yoshikuni Mizuno},
  journal={Movement Disorders},
  year={2006},
  volume={21}
}
We report a long-term outcome on a large cohort of Japanese patients with Parkinson's disease (PD). [] Key Method A total of 1,768 (793 men, 975 women) consecutive patients visited our clinic from 1 January 1989 to 31 December 2002. Among them, 1,183 patients (531 men, 652 women) came to our clinic within 5 years from the onset of disease and at the Hoehn & Yahr Stage III or less at the first visit. Long-term outcome was evaluated in this subcohort of the patients.
Factors Related to the 3-year Prognosis of Mobility of Parkinson's Disease Patients
TLDR
Factors related to mobility prognosis of PD patients can be used in the planning of physical therapy programs aimed at independent living in patients with Parkinson’s disease.
Motor/Nonmotor Symptoms and Progression in Patients with Parkinson's Disease: Prevalence and Risks in a Longitudinal Study
TLDR
It is indicated that age, sex, and some nonmotor symptoms may predict many Parkinson's disease-related events.
Natural History of Parkinson's Disease in the Province of Segovia: Disability in a 20 Years Longitudinal Study
TLDR
Patients with Parkinson's disease evolve gradually toward disability, and prognostic factors of this evolution were identified.
Motor and non-motor symptoms of 1453 patients with Parkinson's disease: prevalence and risks.
The Correlation of ON and OFF Status With Clinical Characteristics in Patients With Parkinson's Disease
TLDR
It is found that the UPDRS scores of practically defined ‘off’ state significantly correlated with the duration of the disease and treatment, and in patients without motor fluctuation, UPD RS scores of ‘on’State can reflect the clinical presentation as much as those of “off” state.
Progression of Parkinson's disease as evaluated by Hoehn and Yahr stage transition times
TLDR
H&Y transition time is a useful measure of disease progression in PD and may be utilized in clinical studies evaluating therapeutic interventions and prognostic factors in PD.
Frequency of Non-motor Symptoms in Parkinson's Patients With Motor Fluctuations
TLDR
The present findings further support the high prevalence of NMS in PD patients with motor fluctuations, thus reinforcing the need for assessing them for diagnostic accuracy and for delivering holistic care.
Clinical and pathological features of Parkinson's disease.
TLDR
The clinical features of PD (motor and nonmotor) and their pathological correlates are reviewed and a thread of pathology starting from the vagal nerve to progress to the brainstem, and eventually to limbic and neocortical brain regions is suggested.
Motor and Non-Motor Symptoms of 1453 Patients with Parkinson ’ s Disease : Any Relationship with the Cumulative Doses of Anti-Parkinsonian Medications ?
TLDR
There was no relationship between the cumulative dose of anti-parkinsonian drugs and the prevalence of symptoms in Japanese patients with Parkinson’s disease.
...
...

References

SHOWING 1-10 OF 63 REFERENCES
Parkinson's disease in Aberdeen: survival after 3.5 years
TLDR
Factors predicting death within the follow‐up period were cognitive impairment, old age, late age of onset, long history of smoking, lower blood pressure, and a variety of signs, symptoms and sequelae of Parkinson's disease associated with decreased mobility.
The occurrence of motor fluctuations in parkinsonian patients treated long term with levodopa
TLDR
The results suggest that, as far as motor fluctuations are concerned, disease prognosis is not influenced by early levodopa treatment, and the introduction oflevodopa as soon as there is a subjective need for the patients to maintain their level of social and work performance is supported.
Five years' treatment of Parkinson's disease with levodopa. Therapeutic results and survival of 100 patients.
TLDR
Despite its inability to cure Parkinson's disease, levodopa provides symptomatic relief for a prolonged time and it remains the single most effective medication for the illness.
Risk factors for progression in Parkinson's disease
TLDR
Assessment of prevalence and duration of exposure to putative risk factors for rapid progression of Parkinson's disease in patients not taking levodopa or direct dopamine agonists found older patients at PD onset progressed more rapidly than younger patients.
Dyskinesias and motor fluctuations in Parkinson's disease. A community-based study.
TLDR
Investigation of the prevalence of dyskinesias and motor fluctuations in a community-based population of patients with Parkinson's disease concludes that motor fluctuations are most strongly related to disease duration and dose of levodopa, and dysKinesias to duration oflevodopa treatment.
The Sydney multicentre study of Parkinson’s disease: progression and mortality at 10 years
TLDR
Mortality in Parkinson’s disease remains increased despite low dose levodopa- carbidopa-carbidopa therapy and no additional benefit was gained from early use of bromocriptine.
Mortality in patients with Parkinson's disease
TLDR
After the introduction of L‐dopa the mortality rate in Parkinson's disease patients has changed, but is still higher than in the background population, and it is likely that several factors can influence the changed mortality.
Prognosis with Parkinson's disease in europe: A collaborative study of population-based cohorts. Neurologic Diseases in the Elderly Research Group.
TLDR
Women with PD had a fivefold higher risk to live in a care facility than did men with PD and the rate of institutionalization varied across studies, increased with age, and was considerably higher in PD cases compared to noncases.
Survival time, mortality, and cause of death in elderly patients with Parkinson's disease. A 9‐year follow‐up
TLDR
Many PD patients reached a high age but had a shorter survival than the controls; there was a significant increase in deaths from pneumonia, and survival analysis showed a short survival time for PD patients.
An examination of male‐female differences in progression and mortality of Parkinson's disease
TLDR
It is concluded that, despite the male preponderance in PD, men and women acquire it at the same age, have the same progression and duration of disease, and die at theSame age; whereas, in the general population, women have a longer life expectancy than men.
...
...